Ribociclib shows promise in indian women with advanced breast cancer
NCT ID NCT07363434
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looked at how well the drug ribociclib works in real-world settings for Indian women with a common type of advanced breast cancer (HR+, HER2-). Researchers reviewed medical records of 335 patients treated across 18 sites in India. The goal was to measure how long the drug kept the cancer from progressing and to check its safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ribociclib (a targeted cancer drug) plus endocrine therapy
What this could lead to
If successful, this study could confirm that ribociclib works well in Indian patients, supporting its routine use for advanced breast cancer.
What could go wrong
This is a completed real-world study, not a controlled trial, so results may be influenced by patient selection and missing data. It does not test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States